DENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue fell 4.06%, EPS grew 181.8%, free cash flow grew 252.9% and total debt fell 10.0%, each against the same quarter a year earlier. Dividend growth for twenty-five consecutive years; insiders bought in the last twelve months.
Follow XRAY
DENTSPLY SIRONA Inc. (XRAY) Piotroski F-score
DENTSPLY SIRONA Inc.'s Piotroski F-score for fiscal 2025 is 6 out of 9: 6 of nine tests of profitability, leverage and efficiency passed, up from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 6 | 2.00 |
| FY2024 | 4 | (1.00) |
| FY2023 | 5 | 0.00 |
| FY2022 | 5 | (4.00) |
| FY2021 | 9 | 6.00 |
| FY2020 | 3 | (5.00) |
| FY2019 | 8 | 3.00 |
| FY2018 | 5 | 1.00 |
| FY2017 | 4 | 0.00 |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (10.70%) | (13.87%) | Fail | 0 |
| Positive operating cash flow | 235.00m | 461.00m | Pass | 1 |
| Rising return on assets | (10.70%) | (13.87%) | Pass | 1 |
| Cash flow above net income | 833.00m | 1.37b | Pass | 1 |
| Falling long-term leverage | 0.36 | 0.24 | Fail | 0 |
| Rising current ratio | 1.51 | 1.10 | Pass | 1 |
| No new shares issued | 199,400,000 | 203,200,000 | Pass | 1 |
| Rising gross margin | 50.00% | 51.62% | Fail | 0 |
| Rising asset turnover | 0.66 | 0.58 | Pass | 1 |
| Piotroski F-score | Mixed | 6 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| AZTA Azenta, Inc. compare | 7 |
| NVST Envista Holdings Corporation compare | 7 |
| ATRC AtriCure, Inc. compare | 7 |
| XRAY DENTSPLY SIRONA Inc. | 6 |
| WRBY Warby Parker Inc. compare | 6 |
| LMAT LeMaitre Vascular, Inc. compare | 6 |
| KMTS Kestra Medical Technologies, Ltd. compare | 4 |
| STAA STAAR Surgical Company compare | 2 |
| PLSE Pulse Biosciences, Inc compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover